Literature DB >> 8328794

Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.

X Y Zhou1, M D Kitzis, L Gutmann.   

Abstract

With numerous imipenem-resistant clinical isolates of Pseudomonas aeruginosa as well as in vitro-selected resistant mutants, we have demonstrated, by a simple method with a powerful cephalosporinase inhibitor, BRL42715, the contribution of chromosomal cephalosporinase in resistance to imipenem in this species.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8328794      PMCID： PMC187975          DOI： 10.1128/AAC.37.6.1387

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.

Authors:  D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa.

Authors:  J Trias; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

Authors:  J P Quinn; E J Dudek; C A DiVincenzo; D A Lucks; S A Lerner
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

4.  Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia.

Authors:  L Gutmann; R Williamson; N Moreau; M D Kitzis; E Collatz; J F Acar; F W Goldstein
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

5.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

6.  Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein.

Authors:  K H Büscher; W Cullmann; W Dick; W Opferkuch
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  Interactions of meropenem with class I chromosomal beta-lactamases.

Authors:  Y J Yang; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem.

Authors:  E H Lee; M H Nicolas; M D Kitzis; G Pialoux; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins.

Authors:  A Raimondi; A Traverso; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.

Authors:  S Satake; H Yoneyama; T Nakae
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790
  10 in total
  9 in total

1.  Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Authors:  C Dib; J Trias; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

2.  Carbapenem resistance in a clinical isolate of Citrobacter freundii.

Authors:  J L Mainardi; P Mugnier; A Coutrot; A Buu-Hoï; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp.

Authors:  W Michael Dunne; Daniel J Hardin
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

5.  In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.

Authors:  W J Weiss; P J Petersen; N V Jacobus; Y I Lin; P Bitha; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

Authors:  C Gimeno; D Navarro; F Savall; E Millás; M A Farga; J Garau; R Cisterna; J García-de-Lomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

7.  Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa.

Authors:  H Huang; R E Hancock
Journal:  J Bacteriol       Date:  1993-12       Impact factor: 3.490

8.  Antibodies against chromosomal beta-lactamase.

Authors:  B Giwercman; J W Rasmussen; O Cioufu; I Clemmentsen; H Schumacher; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 9.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.